Clinical Implications of Chemokines in Acute and Chronic Hepatitis C Virus Infection

다국어 초록 (Multilingual Abstract)

Hepatitis C virus (HCV), a non-cytopathic positive-stranded RNA virus, is one of the most common causes of chronic liver diseases such as chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Upon HCV infection, the majority of patients fail to clear the virus and progress to chronic hepatitis C. Chemokines are small chemotactic cytokines that direct the recruitment of immune cells and coordinate immune responses upon viral infection. Chemokine production during acute HCV infection contributes to the recruitment of immune cells with antiviral effector functions and subsequent viral clearance. In chronic HCV infection, however,continuous production of chemokines due to persistent viral replication might result in incessant recruitment of inflammatory cells to the liver, giving rise to persistence of chronic inflammation and liver injury. In this review, we will summarize the roles of chemokines in acute and chronic settings of HCV infection and the clinical relevance of chemokines in the treatment of hepatitis C.

참고문헌 (Reference)

1 Hepatitis C, "global prevalence" 72 : 341-344, 1997

2 Shin EC, "Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection" 116 : 3006-3014, 2006

3 Thimme R, "Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease" 99 : 15661-15668, 2002

4 Springer TA, "Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm" 76 : 301-314, 1994

5 Afdhal NH, "The natural history of hepatitis C" 24 (24): 3-8, 2004

6 Volkov Y, "The hepatitis C envelope 2 protein inhibits LFA-1-transduced protein kinase C signaling for T-lymphocyte migration" 130 : 482-492, 2006

7 Qin S, "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions" 101 : 746-754, 1998

8 Bonacchi A, "The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C" 125 : 1060-1076, 2003

9 Rossi D, "The biology of chemokines and their receptors" 18 : 217-242, 2000

10 Goulding C, "The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source" 54 : 1157-1161, 2005

11 Askarieh G, "Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C" 51 : 1523-1530, 2010

12 Yoneda S, "Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C" 41 : 587-593, 2011

13 Wagoner J, "Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection" 81 : 309-318, 2007

14 Takahashi K, "Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection" 107 : 7431-7436, 2010

15 Decalf J, "Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients" 204 : 2423-2437, 2007

16 Butera D, "Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C" 106 : 1175-1182, 2005

17 Leroy V, "Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C" 38 : 829-841, 2003

18 Seeff LB, "Natural history of chronic hepatitis C" 36 : S35-S46, 2002

19 Glass WG, "Mouse hepatitis virus infection of the central nervous system: chemokine-mediated regulation of host defense and disease" 15 : 261-272, 2002

20 Butcher EC, "Lymphocyte homing and homeostasis" 272 : 60-66, 1996

21 Boisvert J, "Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes" 38 : 67-75, 2003

22 Wald O, "Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus" 34 : 1164-1174, 2004

23 Zeremski M, "Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C" 48 : 1440-1450, 2008

24 Romero AI, "Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection" 194 : 895-903, 2006

25 Stacey AR, "Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections" 83 : 3719-3733, 2009

26 Zeremski M, "Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection" 2011

27 Apolinario A, "Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease" 97 : 2861-2870, 2002

28 Apolinario A, "Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy" 19 : 551-562, 2004

29 Nishioji K, "Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes" 123 : 271-279, 2001

30 Lagging M, "IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection" 44 : 1617-1625, 2006

31 Zhang M, "High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1" 124 : 867-868, 2003

32 Akbar H, "High baseline interleukine-8 level is an Independent risk factor for the achievement of sustained virological response in chronic HCV patients" 11 : 1301-1305, 2011

33 Sillanpää M, "Hepatitis C virus proteins interfere with the activation of chemokine gene promoters and downregulate chemokine gene expression" 89 : 432-443, 2008

34 Major ME, "Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees" 39 : 1709-1720, 2004

35 Mangia A, "HCV chronic infection and CCR5-delta32/delta32" 124 : 868-869, 2003

36 Shepard CW, "Global epidemiology of hepatitis C virus infection" 5 : 558-567, 2005

37 Woitas RP, "Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C" 122 : 1721-1728, 2002

38 Kunkel EJ, "Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes" 160 : 347-355, 2002

39 Harvey CE, "Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation" 74 : 360-369, 2003

40 Helbig KJ, "Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation" 39 : 1220-1229, 2004

41 Narumi S, "Expression of IFN-inducible protein-10 in chronic hepatitis" 158 : 5536-5544, 1997

42 Kusano F, "Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C" 80 : 415-422, 2000

43 Casrouge A, "Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV" 121 : 308-317, 2011

44 Wasley A, "Epidemiology of hepatitis C: geographic differences and temporal trends" 20 : 1-16, 2000

45 Heydtmann M, "Detailed analysis of intrahepatic CD8 T cells in the normal and hepatitis C-infected liver reveals differences in specific populations of memory cells with distinct homing phenotypes" 77 : 729-738, 2006

46 Shin EC, "Delayed induction, not impaired recruitment, of specific CD8 + T cells causes the late onset of acute hepatitis C" W.B. Saunders Ltd 141 (141): 695-1, 2011

47 Lanford RE, "Cross-genotype immunity to hepatitis C virus" 78 : 1575-1581, 2004

48 Zlotnik A, "Chemokines: a new classification system and their role in immunity" 12 : 121-127, 2000

49 Murdoch C, "Chemokine receptors and their role in inflammation and infectious diseases" 95 : 3032-3043, 2000

50 Shields PL, "Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver" 163 : 6236-6243, 1999

51 Curbishley SM, "CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow" 167 : 887-899, 2005

52 Loetscher P, "CCR5 is characteristic of Th1 lymphocytes" 391 : 344-345, 1998

53 Ajuebor MN, "CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver" 34 : 2907-2918, 2004

54 Diago M, "Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C" 55 : 374-379, 2006

55 Grüner NH, "Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C" 181 : 1528-1536, 2000

56 Hellier S, "Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection" 38 : 1468-1476, 2003

57 Vargas A, "Association between plasma levels of eotaxin (CCL-11) and treatment response to interferon-alpha and ribavirin in HIV/HCV co-infected patients" 65 : 303-306, 2010

58 Lechner F, "Analysis of successful immune responses in persons infected with hepatitis C virus" 191 : 1499-1512, 2000

59 Cooper S, "Analysis of a successful immune response against hepatitis C virus" 10 : 439-449, 1999

60 Maheshwari A, "Acute hepatitis C" 372 : 321-332, 2008

61 Murai M, "Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease" 104 : 49-57, 1999

62 Helbig KJ, "A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro" 32 : 137-143, 2005